Relmada Therapeutics engages director Paul Kelly as special advisor at $32k/mo; Kelly loses independent director status

RELMADA THERAPEUTICS, INC.

Paul Kelly, a director, entered Advisory Agreement as Special Advisor to CEO effective Jan 1, 2023, with $32,000 monthly fee.
Kelly will no longer be considered independent director; he resigns from Audit and Compensation Committees.
Charles J. Casamento appointed Chairman of Compensation Committee effective Jan 1, 2023.
Agreement term of one year, renewable automatically; early termination with 30 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.